Markets
markets

Leo KoGuan, billionaire Tesla bull, tweets that he purchased another 1 million shares of Nvidia

Billionaire software entrepreneur, philosopher, and now major Tesla and Nvidia bull Leo KoGuan tweeted that he bought another 1 million shares of the chip designer.

“Hopefully, I can contribute a little to calm the nervous market. Good luck all,” he wrote in his message.

Unless KoGuan can work some magic in global oil markets or conflict resolution in the Middle East, however, “a little” may be all he’s able to contribute in favor of market tranquility.

Stocks, including Nvidia, are down this morning as the spike in oil prices weighs on other risk assets.

Unless KoGuan can work some magic in global oil markets or conflict resolution in the Middle East, however, “a little” may be all he’s able to contribute in favor of market tranquility.

Stocks, including Nvidia, are down this morning as the spike in oil prices weighs on other risk assets.

More Markets

See all Markets
markets

Vertiv, Lumentum, Coherent, EchoStar pop on S&P 500 inclusion, as Match Group is removed

Data center equipment maker Vertiv Holdings, photonic companies Lumentum and Coherent, and telecom company EchoStar rose in premarket trading on Monday after S&P Dow Jones Indices announced on Friday that the four companies will join its flagship S&P 500 index.

The newcomers will replace Match Group, Molina Healthcare, Lamb Weston, and Paycom Software, most of which are trading lower in premarket trading on Monday.

markets

Hims surges after Novo Nordisk reportedly ends feud, agrees to sell its weight-loss drugs on the platform

Hims & Hers is soaring in premarket trading, up around 54% as of 6:00 a.m. ET, after reports that the telehealth company will announce a new partnership with Novo Nordisk to sell the latter’s weight-loss drugs on its platform again.

The potential deal, which was reported by Bloomberg citing an anonymous source familiar with the matter, would mark yet another turn in the pair’s tumultuous business relationship, after a previous partnership imploded in just under two months last year and Novo Nordisk moved to sue Hims just last month over alleged patent infringements around semaglutide, the active ingredient in Ozempic and Wegovy.

Novo’s weight-loss drugs have lost ground in the ultra-competitive space of late, as combined sales of rival Eli Lilly’s drugs like Mounjaro and Zepbound continue to outweigh Novo’s figures for Wegovy and Ozempic, and copycat offerings from companies like Hims also take market share (at least for now).

A Novo spokesperson said on Friday that the company is “always in conversation with companies that can help improve patient access to FDA-approved medicines,” per Bloomberg, while Michael Cherny, an analyst at Leerink Partners, described the rumored deal as “both a surprise and an unabashed positive for Hims’ stock.”

markets

US gas prices surge, with prediction markets implying >$4 per gallon by the end of March

Pain at the pump is intensifying as the ongoing war in the Middle East pressures supplies.

US average national gas prices rose to nearly $3.48 per gallon on Monday, according to data from the American Automobile Association, and are up more than 16% since the kinetic conflict started.

“Given Sunday evening’s data and the continued surge in oil prices, I believe there is roughly an 80% chance the national average price of gasoline reaches $4 per gallon within the next month- or sooner,” wrote Patrick De Haan, head of petroleum analysis at GasBuddy, in a post on Substack on Sunday evening. “In the immediate term, the national average of $3.45 per gallon could climb to roughly $3.75–$3.95 this week alone.”

Prediction markets currently expect prices to end the month around $4.10 to $4.30. On Friday, the prediction market-implied likely range for prices was between $3.60 and $3.70.

(Event contracts are offered through Robinhood Derivatives, LLC — probabilities referenced or sourced from KalshiEx LLC or ForecastEx LLC.)

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.